دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Hypoxia inducible factor prolyl hydroxylase inhibitors: what a meta-analysis could tell us
Francesco Locatelli 1 and Carmine Zoccali
doi : 10.1093/ckj/sfad229
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad229
Meta-analyses offer an estimate of the overall effect size and help address the inconsistency in findings across studies. The risk is the overemphasis on statistical significance while underrepresenting or misinterpreting clinical significance.
Urine MMP7 as a kidney injury biomarker
Alejandro Avello 1 , Juan Guerrero-Mauvecin1 and Ana Belen Sanz
doi : 10.1093/ckj/sfad233
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad233
Matrix metalloproteinase 7 (MMP-7) is a secreted endopeptidase involved in the degradation of extracellular matrix components and the activation of cytokines and growth factors. The regulation of MMP-7 can be transcriptionally regulated by AP-1 or Wnt/β-catenin or post-translationally by proteolytic activation.
Unmasking the CONVINCE trial: is hemodiafiltration ready to steal the spotlight in real-world practice?
Priti Meena1 and Francesco Locatelli
doi : 10.1093/ckj/sfad247
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad247
Replacing a kidney biopsy by exome sequencing in undetermined kidney diseases—not yet ready for prime time!
Roser Torra 1 , Andreas Kronbichler2 and Ingeborg M. Bajema
doi : 10.1093/ckj/sfad250
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad250
SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future?
Marieta P. Theodorakopoulou and Pantelis Sarafidis
doi : 10.1093/ckj/sfad272
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad272
Direct oral anticoagulants: the safer choice in chronic kidney disease?
Thomas A. Mavrakanas
doi : 10.1093/ckj/sfad288
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad288
Kidney and urine cell transcriptomics in IgA nephropathy and lupus nephritis: a narrative review
Francesco P. Schena 1,2 , Samantha Chiurlia3 , Daniela I. Abbrescia4 and Sharon N. Cox
doi : 10.1093/ckj/sfad121
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad121
This narrative review sheds light on the use of transcriptomics in the analysis of kidney biopsies and urinary cell samples from patients with immunoglobulin A nephropathy or lupus nephritis.
Personalizing electrolytes in the dialysis prescription: what, why and how?
R. Gulsah Dilaver and T. Alp Ikizler
doi : 10.1093/ckj/sfad210
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad210
Maintenance hemodialysis patients suffer from multiple comorbidities and treatment-related complications. A personalized approach to hemodialysis prescription could reduce some of these burdens by preventing complications such as excessive changes in blood pressure, arrhythmias, post-dialysis fatigue and decreased quality of life.
New trials in resistant hypertension: mixed blessing stories
Carmine Zoccali 1 , Francesca Mallamaci2 ,3 , Luca De Nicola 4 and Roberto Minutolo
doi : 10.1093/ckj/sfad251
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad251
Resistant hypertension (RH) is linked to an increased risk of cardiovascular and renal complications. Treatment options include non-pharmacological interventions, such as lifestyle modifications, and the use of specific antihypertensive drug combinations, including diuretics.
Mechanisms and treatment of obesity-related hypertension—Part 1: Mechanisms
Aneliya Parvanova1 ,?, Elia Reseghetti2 ,?, Manuela Abbate3 ,4 and Piero Ruggenenti
doi : 10.1093/ckj/sfad282
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad282
The prevalence of obesity has tripled over the past five decades. Obesity, especially visceral obesity, is closely related to hypertension, increasing the risk of primary (essential) hypertension by 65%–75%.
Should we enlarge the indication for kidney biopsy in patients with diabetes? The pro part
Loreto Gesualdo, Marco Fiorentino, Francesca Conserva and Paola Pontrelli
doi : 10.1093/ckj/sfad266
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad266
Diabetic nephropathy (DN) and non-diabetic renal diseases (NDRD) represent intricate challenges in diagnosis and treatment within the context of the global diabetes epidemic. As the prevalence of diabetes continues to escalate, effective management of renal complications becomes paramount.
Should we enlarge the indication for kidney biopsy in diabetics? The con part
Alberto Ortiz
doi : 10.1093/ckj/sfad267
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad267
Kidney biopsy in diabetic kidney disease. Yes, but in very selected cases
Carmine Zoccali
doi : 10.1093/ckj/sfad268
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad268
The debate on kidney biopsy in diabetic kidney disease (DKD) is multifaceted. Loreto Gesualdo and colleagues argue for its broader application, claiming that biopsies can offer precise diagnostic data and guide personalized treatment plans.
Ketogenic metabolic therapy for chronic kidney disease – the pro part
Thomas Weimbs 1 , Jessianna Saville2 and Kamyar Kalantar-Zadeh
doi : 10.1093/ckj/sfad273
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad273
Ketogenic metabolic therapy (KMT) is a medical nutrition therapy to address certain health and disease conditions. It is increasingly used for many non-communicable diseases that are rooted in abnormal metabolic health.
Risks of the ketogenic diet in CKD – the con part
Shivam Joshi1 ,2 , Rachel Shi 3 and Jason Patel
doi : 10.1093/ckj/sfad274
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad274
The ketogenic diet is a very low carbohydrate diet that has received a lot of attention for its role in the treatment of type 2 diabetes and obesity. For patients with chronic kidney disease, there is limited evidence on the risks and/or benefits of this diet.
Urinary matrix metalloproteinase-7 is a sensitive biomarker to evaluate renal tubular injury in patients with minimal change disease and focal segmental glomerulosclerosis
Dan-yang Yin1,?, Gai-ling Hou1,?, Xiao-qing Yang 2 , Liang-liang Bi 2 , Xiao-feng Mei 2 , Meng-ke Bai 2 , Li Zhou 3 , Shan Zhu 4 and Yan-jie Huang
doi : 10.1093/ckj/sfad027
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad027
To explore the advantages of urinary matrix metalloproteinase-7 (MMP-7) in evaluating renal tubular injury in minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) patients compared with urinary cystatin C (CysC) and retinol-binding protein (RBP).
Beyond the kidney biopsy: genomic approach to undetermined kidney diseases
Thomas Robert 1,2 , Laure Raymond3 , Marine Dancer 3 , Julia Torrents4 , Noémie Jourde-Chiche1,5 , Stéphane Burtey 1,5 , Christophe Béroud 2 and Laurent Mesnard
doi : 10.1093/ckj/sfad099
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad099
According to data from large national registries, almost 20%–25% of patients with end-stage kidney disease have an undetermined kidney disease (UKD). Recent data have shown that monogenic disease-causing variants are under-diagnosed. We performed exome sequencing (ES) on UKD patients in our center to improve the diagnosis rate.
Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review
See Cheng Yeo 1 , Hankun Wang 1 , Yee Gary Ang 2 , Chee Kong Lim3 and Xi Yan Ooi
doi : 10.1093/ckj/sfad137
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad137
Chronic kidney disease (CKD) is a significant public health problem, with rising incidence and prevalence worldwide, and is associated with increased morbidity and mortality. Early identification and treatment of CKD can slow its progression and prevent complications, but it is not clear whether CKD screening is cost-effective.
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials
Roberto Minutolo 1 , Maria Elena Liberti1 , Vittorio Simeon2 , Ferdinando C. Sasso3 , Silvio Borrelli1 , Luca De Nicola 1 and Carlo Garofalo
doi : 10.1093/ckj/sfad143
Clinical Kidney Journal, Volume 17, Issue 1, January
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta-analysis and meta-regression the efficacy and safety of HIF-PHIs in patients with CKD-related anaemia.
Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis
Anna Pisano1 , Carmine Zoccali 2 ,3 ,4 , Davide Bolignano 5 , Graziella D’Arrigo1 and Francesca Mallamaci
doi : 10.1093/ckj/sfad179
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad179
Several studies have examined the frequency of sleep apnoea (SA) in patients with chronic kidney disease (CKD), reporting different prevalence rates. Our systematic review and meta-analysis aimed to define the clinical penetrance of SA in CKD and end-stage kidney disease (ESKD) patients.
Measurement of urinary exosomal phospholipase A2 receptor is a sensitive method for diagnosis of PLA2R-associated membranous nephropathy
Bin Wang1 ,?, Yu-Qi Fu1 ,?, Li-jun Xie1 ,?, Jin-Yuan Cao1 ,2 , Min Yang3 , Min Li3 , Tian-Lei Chen3 , Xiao-Liang Zhang1 , Qian Luo 4 , Lin-Li Lv1 and Bi-Cheng Liu
doi : 10.1093/ckj/sfad191
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad191
The discovery of phospholipase A2 receptor (PLA2R) and its antibody (aPLA2Rab) has paved the way for diagnosing PLA2R-associated membranous nephropathy (PLA2R-MN) with a high specificity of 98%.
Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men
Jose M. Valdivielso 1 , Sol Carriazo 2 ,3 , Marisa Martin1 , Beatriz Fernandez-Fernandez2 ,3 , Marcelino Bermudez-L?pez1 and Alberto Ortiz 2 ,3 ,?; on behalf of NEFRONA investigators*
doi : 10.1093/ckj/sfad212
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad212
Hyperkalemia is common among patients with chronic kidney disease (CKD) but there is scarce information on differential risk factors and outcomes for men and women. For instance, smoking has been suggested to be a risk factor for hyperkalemia, but specific analysis of the sex-specific impact of smoking on hyperkalemia in CKD is lacking.
Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial
Liangying Gan 1 , Li Xing2 , Yan Xu3 , Linghui Zhou4 , Hong Jiang5 , Xiuli Sun6 , Tianjun Guan7 , Ping Luo8 , Junxia Wang9 , Fuyun Sun10 , Zhiyong Guo11 , Minghao Guo12 , Ju Gao13 , Gang Wei14 , Wen Zhong14 , Yongchun Zhou15 and Li Zuo
doi : 10.1093/ckj/sfad216
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad216
The efficacy and safety of tenapanor has not been confirmed in Chinese end-stage renal disease (ESRD) patients with hyperphosphatemia on haemodialysis (HD).
Blood pressure reduction after renal denervation in patients with or without chronic kidney disease
Merve Günes-Altan1 , Axel Schmid2 , Christian Ott1 , Agnes Bosch 1 , Robert Pietschner1 , Mario Schiffer1 , Michael Uder2 , Roland E. Schmieder1 and Dennis Kannenkeril
doi : 10.1093/ckj/sfad237
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad237
Renal denervation (RDN) has emerged as an adjacent option for the treatment of hypertension. This analysis of the Erlanger registry aimed to compare the blood pressure (BP)-lowering effects and safety of RDN in patients with and without chronic kidney disease (CKD).
Twenty years of the French Renal Epidemiology and Information Network
Isabelle Kazes1 , Justine Solignac 2 , Mathilde Lassalle3 , Lucile Mercadal4 and Cécile Couchoud 3 ; on behalf of the REIN registry
doi : 10.1093/ckj/sfad240
The French Renal Epidemiology and Information Network (REIN) is 20Â years old. It is not just a national data registry, but rather an epidemiological and informational network serving patients with chronic kidney disease, nephrology teams and health services.
Study of the association between serum levels of kynurenine and cardiovascular outcomes and overall mortality in chronic kidney disease
Carolla El Chamieh 1 , Islam Amine Larabi2 ,3 , Natalia Alencar De Pinho 1 , Oriane Lambert1 , Christian Combe 4 ,5 , Denis Fouque6 ,7 , Luc Frimat8 ,9 , Christian Jacquelinet1 ,10 , Maurice Laville7 , Solène Laville11 ,12 , Céline Lange1 , Jean-Claude Alvarez2 ,3 , Ziad A. Massy 1 ,13 ,? and Sophie Liabeuf 11 ,12 ,?; on behalf of the Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group
doi : 10.1093/ckj/sfad248
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad248
Kynurenine is a protein-bound uremic toxin. Its circulating levels are increased in chronic kidney disease (CKD). Experimental studies showed that it exerted deleterious cardiovascular effects. We sought to evaluate an association between serum kynurenine levels and adverse fatal or nonfatal cardiovascular events and all-cause mortality in CKD patients.
Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial
Frederik Husum M?rup 1 ,2 , Martin Bjergskov Thomsen1 and Henrik Birn
doi : 10.1093/ckj/sfad249
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad249
Dapagliflozin and finerenone reduce albuminuria and slow CKD progression, but additive effects remain unstudied. We compared their individual and combined efficacy and safety in patients with non-diabetic CKD.
Oral anticoagulant treatment and risk of kidney disease—a nationwide, population-based cohort study
Ane Emilie Friis Vestergaard 1 , Simon Kok Jensen 1 , Uffe Heide-J?rgensen1 , Kasper Adelborg1 ,2 , Henrik Birn3 ,4 , Juan-Jesus Carrero 5 and Christian Fynbo Christiansen
doi : 10.1093/ckj/sfad252
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad252
Direct oral anticoagulants (DOACs) are recommended as first-line treatment of atrial fibrillation. Whether DOAC use is associated with lower risks of kidney complications compared with vitamin K antagonists (VKAs) remains unclear. We examined this association in a nationwide, population-based cohort study.
Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria
Daniel Rodr?guez1 ,?, Ekaterina Gurevich1 ,?, Soroush Mohammadi Jouabadi2 , Eva Maria Pastor Arroyo3 , Alexander Ritter1 , Sandrine Estoppey Younes4 , Carsten A. Wagner3 , Pedro Henrique Imenez Silva5 , Harald Seeger 1 ,3 ,†and Nilufar Mohebbi
doi : 10.1093/ckj/sfad256
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad256
Kidney stones are frequent in industrialized countries with a lifetime risk of 10 to 15%. A high percentage of individuals experience recurrence. Calcium-containing stones account for more than 80% of kidney stones.
Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort
Seraf? Cambray1 ,2 ,?, Marcelino Berm?dez-L?pez1 ,3 ,?, Alicia Garcia-Carrasco1 and Jose M. Valdivielso 1 ; on behalf of the NEFRONA investigators
doi : 10.1093/ckj/sfad257
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad257
Chronic kidney disease (CKD) is associated with increased atherosclerotic burden and higher risk for cardiovascular events (CVE). Atherosclerosis has a significant genetic component and, in CKD, it is influenced by mineral metabolism alterations.
Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy
Emilio Rodrigo 1 , Luis F. Quintana 2 , Teresa V?zquez-S?nchez3 , Ana S?nchez-Fructuoso 4 , Anna Buxeda 5 , Eva Gavela 6 , Juan M. Cazorla7 , Sheila Cabello 8 , Isabel Beneyto 9 , Mar?a O. L?pez-Oliva 10 , Fritz Diekmann 2 , José M. G?mez-Ortega11 , Natividad Calvo Romero 4 , Mar?a J. Pérez-S?ez 5 , Asunci?n Sancho 6 , Auxiliadora Mazuecos 7 , Jordi Esp?-Reig 9 , Carlos Jiménez 10 and Domingo Hern?ndez
doi : 10.1093/ckj/sfad259
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad259
Immunoglobulin A nephropathy (IgAN) is the most frequent recurrent disease in kidney transplant recipients and its recurrence contributes to reducing graft survival. Several variables at the time of recurrence have been associated with a higher risk of graft loss. The presence of clinical or subclinical inflammation has been associated with a higher risk of kidney graft loss, but it is not precisely known how it influences the outcome of patients with recurrent IgAN.
Age- and time-dependent increases in incident anti-glomerular basement membrane disease: a nationwide cohort study
Karl Emil Nelveg-Kristensen1 , Bo Madsen2 , Mark McClure 3 , Nanna Bruun1 , Cecilie Lyngs?4 , Hans Dieperink5 , Jon Waarst Gregersen2 , Elizabeth Krarup6 , Per Ivarsen7 ,8 , Christian Torp-Pedersen9 ,10 , Martin Egfjord1 , Wladimir Szpirt1 and Nicholas Carlson1 ; for the Danish Vasculitis Association (DANVAS)
doi : 10.1093/ckj/sfad261
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad261
Epidemiologic assessments of anti-glomerular basement membrane (GBM) disease have been challenging due to its rare occurrence. We examined changes in the incidence and outcomes from 1998 to 2018 using nationwide healthcare registries.
DKK3 as a potential novel biomarker in patients with autosomal polycystic kidney disease
Sita Arjune 1 ,2 ,3 ,?, Martin R. Sp?th 1 ,3 ,?, Simon Oehm 1 , Polina Todorova 1 , Stefan J. Schunk4 , Katharina Lettenmeier1 , Seung-Hun Chon 5 ,6 , Malte P. Bartram1 , Philipp Antczak 1 ,3 , Franziska Grundmann 1 , Danilo Fliser4 and Roman-Ulrich Müller
doi : 10.1093/ckj/sfad262
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad262
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, and leads to a steady loss of kidney function in adulthood. The variable course of the disease makes it necessary to identify the patients with rapid disease progression who will benefit the most from targeted therapies and interventions.
Factors that influence the selection of conservative management for end-stage renal disease – a systematic review
Pavithra Sakthivel1 , Alyaa Mostafa1 and Olalekan Lee Aiyegbusi
doi : 10.1093/ckj/sfad269
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad269
Most patients with end-stage renal disease (ESRD) are managed with dialysis and less commonly kidney transplantation. However, not all are suitable for or desire either of these renal replacement therapies. Conservative management (CM) is an option. However, the selection of CM is often not easy for patients and clinicians. The aim of this systematic review is to identify the key factors that influence the selection of CM for ESRD.
Incremental versus conventional haemodialysis in end-stage kidney disease: a systematic review and meta-analysis
Kullaya Takkavatakarn 1 ,?, Kavita Jintanapramote2 ,?, Jeerath Phannajit1 ,3 , Kearkiat Praditpornsilpa1 , Somchai Eiam-Ong1 and Paweena Susantitaphong1
doi : 10.1093/ckj/sfad280
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad280
Appropriate dialysis prescription in the transitional setting from chronic kidney disease to end-stage kidney disease is still challenging. Conventional thrice-weekly haemodialysis (HD) might be associated with rapid loss of residual kidney function (RKF) and high mortality. The benefits and risks of incremental HD compared with conventional HD were explored in this systematic review and meta-analysis.
Risk factors for COVID-19 hospitalization and mortality in patients with chronic kidney disease: a nationwide cohort study
Angelica Artborg1 ,2 , Aurora Caldinelli1 ,3 , Julia Wijkstr?m 1 ,2 , Alexandra Nowak1 ,2 , Michael Fored4 , Maria Stendahl5 ,6 , Marie Evans 1 ,2 ,6 and Helena Rydell
doi : 10.1093/ckj/sfad283
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad283
Several studies have demonstrated an increased risk of severe coronavirus disease 2019 (COVID-19) in chronic kidney disease (CKD) patients. However, few have investigated the impact of CKD stage and dialysis modality. The primary aim of this study was to investigate the association between CKD stage, dialysis modality and risk of severe COVID-19. Secondly, we aimed to study the impact of comorbidities and drugs on the risk of severe COVID-19 in the CKD population.
Bone mineral density after exercise training in patients with chronic kidney disease stages 3 to 5: a sub-study of RENEXC—a randomized controlled trial
Vaida Petrauskiene, Matthias Hellberg, Philippa Svensson, Yunan Zhou and Naomi Clyne
doi : 10.1093/ckj/sfad287
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad287
We evaluated the effects of 12 months of exercise training on bone mineral density (BMD) in patients with chronic kidney disease (CKD) stages 3–5 not on kidney replacement therapy (KRT).
Early growth response 1 as a podocyte injury marker in human glomerular diseases
Masahiro Okabe 1 , Kentaro Koike1 , Izumi Yamamoto 1 , Nobuo Tsuboi 1 , Taiji Matsusaka2 and Takashi Yokoo
doi : 10.1093/ckj/sfad289
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad289
In human glomerular diseases, visualizing podocyte injury is desirable since podocytes do not regenerate and podocyte injury leads to podocyte loss. Herein, we investigated the utility of immunostaining for early growth response 1 (EGR1), which is expressed in injured podocytes from the early stages of injury in animal experiments, as a podocyte injury marker in human glomerular diseases.
All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality
Jia-Jin Chen1 , Tao-Han Lee 2 , George Kuo 1 , Chieh-Li Yen1 , Cheng-Chia Lee 1 , Chih-Hsiang Chang 1 , Kun-Hua Tu1 , Yung-Chang Chen1 , Ji-Tseng Fang1 , Cheng-Chieh Hung1 , Chih-Wei Yang1 , Wen-Chi Chou3 , Ching-Chi Chi4 , Yu-Kang Tu 5 and Huang- Yu Yang
doi : 10.1093/ckj/sfad292
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad292
Immune checkpoint inhibitors (ICIs) have been associated with acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been systematically examined. Additionally, exposure to proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs) were considered as risk factors for AKI, but with inconclusive results in ICI-related AKI.
Meta-analysis on the efficacy and safety of rituximab versus tacrolimus for nephrotic syndrome in the paediatric age group
Syeda Tayyaba Rehan1 , Eman Ali1 , Farea Eqbal1 , Muhammad Nadeem Ahsan1 and Muhammad Sohaib Asghar
doi : 10.1093/ckj/sfad263
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad263
Reconsidering the role of the IL-23/IL-17 immune axis in idiopathic nephrotic syndrome pathogenesis
Giuseppe Salfi
doi : 10.1093/ckj/sfad264
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad264
Prophylactic ultra-low dose rituximab to maintain remission in relapsing adult minimal change disease
Wing Yin Leung1 , Henry H.L. Wu 2 , Alexander Woywodt 1 ,3 and Arvind Ponnusamy
doi : 10.1093/ckj/sfad270
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad270
The need for better donor engagement and outreach with legacy living kidney donors
Katya Loban1 ,2 , Ahsan Alam1 ,2 ,3 and Shaifali Sandal
doi : 10.1093/ckj/sfad271
Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad271
